Jules Bordet Institute
3 clinical trials · 3 recruiting · OTHER
Trials by Jules Bordet Institute
RECRUITINGNCT07370597
LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA...
A substantial proportion of patients with mCRPC do not respond to 177Lu-PSMA-RLT. The PSA response to Lu-PSMA was observed in nearly 46% of patients included in VISION trial and...
Sponsor: Jules Bordet InstituteEnrolling: 1101 location
Prostate Cancer (Adenocarcinoma)
RECRUITINGNCT07109440
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM)....
Sponsor: Jules Bordet InstituteEnrolling: 501 location
Liver Metastases From Colorectal Cancer
RECRUITINGNCT06061874
Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor...
Sponsor: Jules Bordet InstituteEnrolling: 801 location
CancerPeritoneal Carcinomatosis